Literature DB >> 12679485

Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma.

Deborah J Marsh1, George Theodosopoulos, Klaus Martin-Schulte, Anne-Louise Richardson, Jeanette Philips, Hans-Dietrich Röher, Leigh Delbridge, Bruce G Robinson.   

Abstract

Medullary thyroid carcinoma (MTC) is a malignant tumor of the calcitonin-secreting parafollicular C cells of the thyroid occurring sporadically and as a component of the multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma syndrome. The primary genetic cause of multiple endocrine neoplasia type 2 is germline mutation of the RET protooncogene. Somatic point mutations in RET also occur in sporadic MTC. Although RET mutation is likely sufficient to cause C-cell hyperplasia, the precursor lesion to MTC, tumor progression is thought to be due to clonal expansion caused by the accumulation of somatic events. Using the genome-scanning technique comparative genomic hybridization, we identified chromosomal imbalances that occur in MTC including deletions of chromosomes 1p, 3q26.3-q27, 4, 9q13-q22, 13q, and 22q and amplifications of chromosome 19. These regions house known tumor suppressor genes as well as genes encoding subunits of the multicomponent complex of glycosylphosphatidylinositol-linked proteins (glial cell line-derived neurotrophic factor family receptors alpha-2-4) and their ligands glial cell line-derived neurotrophic factor, neurturin, persephin, and artemin that facilitate RET dimerization and downstream signaling. Chromosomal imbalances in the MTC cell line TT were largely identical to those identified in primary MTC tumors, consolidating its use as a model for studying MTC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679485     DOI: 10.1210/jc.2002-021155

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

2.  Copy Number Variations in Tilapia Genomes.

Authors:  Bi Jun Li; Hong Lian Li; Zining Meng; Yong Zhang; Haoran Lin; Gen Hua Yue; Jun Hong Xia
Journal:  Mar Biotechnol (NY)       Date:  2017-02-06       Impact factor: 3.619

Review 3.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

4.  Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome.

Authors:  M Poturnajova; V Altanerova; L Kostalova; J Breza; C Altaner
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

5.  High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

Authors:  Lei Ye; Libero Santarpia; Gilbert J Cote; Adel K El-Naggar; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2008-09-02       Impact factor: 5.958

6.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.

Authors:  Chiara Tuccilli; Enke Baldini; Natalie Prinzi; Stefania Morrone; Salvatore Sorrenti; Angelo Filippini; Antonio Catania; Stefania Alessandrini; Roberta Rendina; Carmela Coccaro; Massimino D'Armiento; Salvatore Ulisse
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

7.  Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Authors:  Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

8.  ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Michelle D Williams; Elizabeth G Grubbs; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

9.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

10.  Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

Authors:  Ira L Kraft; Srivandana Akshintala; John W Glod; Jack F Shern; Brigitte C Widemann; Yuelin Zhu; Haiyan Lei; Claudia Derse-Anthony; Eva Dombi; Seth M Steinberg; Maya Lodish; Steven G Waguespack; Oxana Kapustina; Elizabeth Fox; Frank M Balis; Maria J Merino; Paul S Meltzer
Journal:  Clin Cancer Res       Date:  2017-11-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.